Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy

References

• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi: 10.1056/NEJMoa1509388
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443. doi: 10.1056/NEJMoa1817073
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. doi: 10.1056/NEJMoa1812836
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicenter, randomized, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. doi: 10.1016/S1470-2045(18)30788-5
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363. doi: 10.1002/ajh.25638
   PubMed Web of Science ®Google Scholar
• Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440–3450. doi: 10.1182/bloodadvances.2021006434
   PubMed Web of Science ®Google Scholar
• Molica S, Matutes E, Tam C, et al. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. Hematol Oncol. 2019;38(2):129–136. doi: 10.1002/hon.2695
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171–1175. doi: 10.1038/s41375-021-01485-x
   PubMed Web of Science ®Google Scholar
• Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–1043. doi: 10.1016/S1470-2045(22)00293-5
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in Previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452. doi: 10.1200/JCO.21.01210
   PubMed Web of Science ®Google Scholar
• Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319–332. doi: 10.1056/NEJMoa2211582
   PubMed Web of Science ®Google Scholar
• Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919–1928. doi: 10.1182/blood.2019000840
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107–1120. doi: 10.1056/NEJMoa1713976
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 Jun 6;380(23):2225–2236. doi: 10.1056/NEJMoa1815281
   PubMed Web of Science ®Google Scholar
• Kater A, Harrup R, Kipps TM, et al. Final 7-year follow-up and retreatment substudy analysis of MURANO: venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Oral abstract #S201. European Hematology Association 2023 Congress. Jun 9, 2023, Frankfurt DE.
   Google Scholar
• Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. Oral abstract #S145. European Hematology Association 2023 Congress. Jun 9, 2023, Frankfurt DE
   Google Scholar
• Niemann CU. BTK inhibitors: safety + efficacy = outcome. Blood. 2023, Aug 24;142(8):679–680. doi: 10.1182/blood.2023020974
   PubMed Web of Science ®Google Scholar
• Molica S, Laurenti L, Ghia P, et al. COVID-19 pandemic impact on chronic lymphocytic leukemia (CLL) patients’ preferences towards therapies: the Italian experience (CHOICE study). Blood. 2023 23 Nov 2021;138, Suppl 1(Supplement 1):4690. doi: 10.1182/blood-2021-148308
   Google Scholar
• Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017 Aug;178(3):394–402. doi: 10.1111/bjh.14785
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023 Apr 18;14(1):2147. doi: 10.1038/s41467-023-37648-w
   PubMed Web of Science ®Google Scholar
• Kipps T, Owen C, Flinn IW, et al. Long-term outcomes with continuous ibrutinib in patients with CLL: analysis of time to progression. Poster 627. European Hematology Association 2023 Congress. Jun 9, 2023, Frankfurt DE
   Google Scholar
• Jacobs R, Lu X, Emond B, et al. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib. Future Oncol. Online ahead of print. 2023 Jul 21. doi: 10.2217/fon-2023-0436
   Web of Science ®Google Scholar
• Roever L. Endpoints in clinical trials: advantages and limitations. Evid Based Med And Practice. 2016;1(s1):e111. doi: 10.4172/ebmp.1000e111
   Google Scholar
• Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov;5(11):e563–e598. doi: 10.1016/S2352-3026(18)30051-6
   PubMed Web of Science ®Google Scholar
• https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60
   Google Scholar
• Ruppert AS, Booth AM, Ding W, et al. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: alliance A041202. Leukemia. 2021 Oct;35(10):2854–2861. doi: 10.1038/s41375-021-01342-x
   PubMed Web of Science ®Google Scholar
• Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023 Aug 24;142(8):687–699. doi: 10.1182/blood.2022018818
   PubMed Web of Science ®Google Scholar
• Seymour JF, Gaitonde P, Emeribe U, et al. A Quality-AdjustedmSurvival (Q-TWiST) analysis to assess benefit-risk of acalabrutinib versus idelalisib/bendamustine plus rituximab or ibrutinib among relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients [abstract]. Blood. 2021;138(suppl 1):3722. doi: 10.1182/blood-2021-147112
   Google Scholar
• Molica S, Allsup D, Polliack A, et al. The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: results of network meta-analysis. Eur J Haematol. 2023 Jun;110(6):774–777. doi: 10.1111/ejh.13943
   PubMed Web of Science ®Google Scholar
• Cufer T, Ciuleanu TE, Berzinec P, et al. Access to novel drugs for non-small cell lung cancer in central and Southeastern Europe: a central European cooperative Oncology group analysis. Oncology. 2020 Mar;25(3):e598–e601. doi: 10.1634/theoncologist.2019-0523
   Google Scholar
• Kiesewetter B, Dafni U, de Vries EGE, et al. ESMO-Magnitude of clinical benefit Scale for haematological malignancies (ESMO-MCBS: H) version 1.0. Ann Oncol. 2023 Sep;34(9):734–771. doi: 10.1016/j.annonc.2023.06.002
   PubMedGoogle Scholar